EVGN On Other Exchanges
Tel Aviv

evogene ltd (EVGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EVOGENE LTD (EVGN)

Related News

No related news articles were found.

evogene ltd (EVGN) Related Businessweek News

No Related Businessweek News Found

evogene ltd (EVGN) Details

Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics. The company operates through three segments: Evogene, Evofuel, and Biomica. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants and bio-pesticides. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Biomica segment discovers and develops human microbiome-based therapeutics for the treatment of immune-mediated and infectious diseases. The company also provides medical cannabis products. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF, Corteva, ICL, Monsanto, Bayer, and others. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

150 Employees
Last Reported Date: 04/29/19
Founded in 1999

evogene ltd (EVGN) Top Compensated Officers

CEO & President
Total Annual Compensation: $403.0K
Executive Vice President of Technology
Total Annual Compensation: $245.0K
Compensation as of Fiscal Year 2018.
evogene ltd
Evogene Amends its Collaboration Agreement with Crop Science Division of Bayer to Include Genome Editing Targets

Evogene Ltd. announced that after achieving positive results, its corn disease resistance research collaboration with the Crop Science Division of Bayer is being refocused on the identification of genome editing targets for evaluation against a broad range of corn diseases. Evogene will use its CPB (Computational Predictive Biology) platform to identify the required edits to improve disease resistance in corn. The edits will be based on Evogene-discovered genes and the accumulated knowledge achieved through this collaboration, focusing on altering gene expression or function. Any promising targets would be pursued by Bayer's in-house team for validation. The collaboration aims to develop improved corn seeds with resistance to fungal diseases. The collaboration, pursued through Evogene's Ag-Seeds division, is focused on the discovery and development of candidate genes predicted to provide resistance to multiple fungal diseases in corn. Evogene previously announced that genes it discovered under the collaboration had successfully demonstrated stalk rot resistance in model plants and had been advanced to Bayer's corn pipeline, where they are being tested against additional diseases. Following positive results in greenhouse testing conducted by Bayer, a subset of these genes will be tested in corn field trials.

Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2019

Evogene Ltd. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced sales was USD 348,000 compared to USD 366,000 a year ago. Operating loss was USD 4.669 million compared to USD 4.946 million a year ago. Net loss was USD 3.709 million compared to USD 5.386 million a year ago. Basic loss per share was USD 0.15 compared to USD 0.21 a year ago.

Adina Makover Not to Stand for Re-Election as Director of Evogene Ltd

Dr. Adina Makover is not standing for re-election as Director of Evogene Ltd. and her tenure as a director of the company will therefore conclude at the end of the Meeting to be held on June 26, 2019.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

EVGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EVGN.
View Industry Companies

Industry Analysis


Industry Average

Valuation EVGN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EVOGENE LTD, please visit www.evogene.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.